In Vivo Inhibition of TRPC6 by SH045 Attenuates Renal Fibrosis in a New Zealand Obese (NZO) Mouse Model of Metabolic Syndrome

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jun 24

PMID 35743312

Authors

Zhihuang Zheng

Yao Xu

Ute Krugel

Michael Schaefer

Tilman Grune

Bernd Nurnberg

May-Britt Kohler

Maik Gollasch

Dmitry Tsvetkov

Lajos Marko

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome is a significant worldwide public health challenge and is inextricably linked to adverse renal and cardiovascular outcomes. The inhibition of the transient receptor potential cation channel subfamily C member 6 (TRPC6) has been found to ameliorate renal outcomes in the unilateral ureteral obstruction (UUO) of accelerated renal fibrosis. Therefore, the pharmacological inhibition of TPRC6 could be a promising therapeutic intervention in the progressive tubulo-interstitial fibrosis in hypertension and metabolic syndrome. In the present study, we hypothesized that the novel selective TRPC6 inhibitor SH045 (larixyl N-methylcarbamate) ameliorates UUO-accelerated renal fibrosis in a New Zealand obese (NZO) mouse model, which is a polygenic model of metabolic syndrome. The in vivo inhibition of TRPC6 by SH045 markedly decreased the mRNA expression of pro-fibrotic markers (, , , , , ) and chemokines (, , ) in UUO kidneys of NZO mice compared to kidneys of vehicle-treated animals. Renal expressions of intercellular adhesion molecule 1 (ICAM-1) and α-smooth muscle actin (α-SMA) were diminished in SH045- versus vehicle-treated UUO mice. Furthermore, renal inflammatory cell infiltration (F4/80+ and CD4+) and tubulointerstitial fibrosis (Sirius red and fibronectin staining) were ameliorated in SH045-treated NZO mice. We conclude that the pharmacological inhibition of TRPC6 might be a promising antifibrotic therapeutic method to treat progressive tubulo-interstitial fibrosis in hypertension and metabolic syndrome.

Citing Articles

Roles of TRP and PIEZO receptors in autoimmune diseases.

Yang B, Ma D, Zhu X, Wu Z, An Q, Zhao J Expert Rev Mol Med. 2024; 26:e10.

PMID: 38659380 PMC: 11140548. DOI: 10.1017/erm.2023.23.

Lanthanum hydroxide protects kidney through gut microbiota in a rat model of chronic kidney disease.

Gao Y, Wang S, Sun L, Li B, Liu H, Bu R Pharmacol Res Perspect. 2024; 12(2):e1187.

PMID: 38546116 PMC: 10976425. DOI: 10.1002/prp2.1187.

[Platycodin D improves pulmonary fibrosis in mice by down-regulating TRPC6 expression and reducing ROS production in lung fibroblasts].

Liang Z, Yu C, Liang S, Zhou Z, Meng X, Zou F Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(1):60-69.

PMID: 38293977 PMC: 10878886. DOI: 10.12122/j.issn.1673-4254.2024.01.08.

Proximal Tubular Ablation Exacerbates Ischemia/Reperfusion Injury (IRI)-Induced Renal Maladaptive Repair through the Upregulation of P53.

Zhang C, Zheng Z, Xu K, Cheng G, Wu H, Liu J Int J Mol Sci. 2023; 24(20).

PMID: 37894939 PMC: 10607662. DOI: 10.3390/ijms242015258.

An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis.

Batool L, Hariharan K, Xu Y, Kassmann M, Tsvetkov D, Gohlke B Cell Mol Life Sci. 2023; 80(9):265.

PMID: 37615749 PMC: 10449997. DOI: 10.1007/s00018-023-04901-w.

References

Damann N, Owsianik G, Li S, Poll C, Nilius B . The calcium-conducting ion channel transient receptor potential canonical 6 is involved in macrophage inflammatory protein-2-induced migration of mouse neutrophils. Acta Physiol (Oxf). 2008; 195(1):3-11. DOI: 10.1111/j.1748-1716.2008.01918.x. View

Zeisberg E, Potenta S, Sugimoto H, Zeisberg M, Kalluri R . Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008; 19(12):2282-7. PMC: 2588112. DOI: 10.1681/ASN.2008050513. View

Li X, Pan J, Li H, Li G, Liu X, Liu B . DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. 2020; 11(1):4467. PMC: 7501299. DOI: 10.1038/s41467-020-18304-z. View

Mirhashemi F, Scherneck S, Kluth O, Kaiser D, Vogel H, Kluge R . Diet dependence of diabetes in the New Zealand Obese (NZO) mouse: total fat, but not fat quality or sucrose accelerates and aggravates diabetes. Exp Clin Endocrinol Diabetes. 2010; 119(3):167-71. DOI: 10.1055/s-0030-1263127. View

Carrillo C, Hichami A, Andreoletti P, Cherkaoui-Malki M, Cavia M, Abdoul-Azize S . Diacylglycerol-containing oleic acid induces increases in [Ca(2+)](i) via TRPC3/6 channels in human T-cells. Biochim Biophys Acta. 2012; 1821(4):618-26. DOI: 10.1016/j.bbalip.2012.01.008. View

Agell N, Bachs O, Rocamora N, Villalonga P . Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. 2002; 14(8):649-54. DOI: 10.1016/s0898-6568(02)00007-4. View

Marko L, Park J, Henke N, Rong S, Balogh A, Klamer S . B-cell lymphoma/leukaemia 10 and angiotensin II-induced kidney injury. Cardiovasc Res. 2019; 116(5):1059-1070. DOI: 10.1093/cvr/cvz169. View

Ilatovskaya D, Staruschenko A . TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases. Am J Physiol Renal Physiol. 2015; 309(5):F393-7. PMC: 4556891. DOI: 10.1152/ajprenal.00186.2015. View

Black L, Lever J, Traylor A, Chen B, Yang Z, Esman S . Divergent effects of AKI to CKD models on inflammation and fibrosis. Am J Physiol Renal Physiol. 2018; 315(4):F1107-F1118. PMC: 6230746. DOI: 10.1152/ajprenal.00179.2018. View

10.

Andrikopoulos P, Kieswich J, Pacheco S, Nadarajah L, Harwood S, ORiordan C . The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling. J Am Soc Nephrol. 2018; 30(1):33-49. PMC: 6317609. DOI: 10.1681/ASN.2018020209. View

11.

Breyer M, Bottinger E, Brosius 3rd F, Coffman T, Harris R, Heilig C . Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2004; 16(1):27-45. DOI: 10.1681/ASN.2004080648. View

12.

Tomasek J, Gabbiani G, Hinz B, Chaponnier C, Brown R . Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002; 3(5):349-63. DOI: 10.1038/nrm809. View

13.

Davis J, Burr A, Davis G, Birnbaumer L, Molkentin J . A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev Cell. 2012; 23(4):705-15. PMC: 3505601. DOI: 10.1016/j.devcel.2012.08.017. View

14.

Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

15.

Kong W, Haschler T, Nurnberg B, Kramer S, Gollasch M, Marko L . Renal Fibrosis, Immune Cell Infiltration and Changes of TRPC Channel Expression after Unilateral Ureteral Obstruction in Trpc6-/- Mice. Cell Physiol Biochem. 2019; 52(6):1484-1502. DOI: 10.33594/000000103. View

16.

Chen Q, Zhou Y, Zhou L, Fu Z, Yang C, Zhao L . TRPC6-dependent Ca signaling mediates airway inflammation in response to oxidative stress via ERK pathway. Cell Death Dis. 2020; 11(3):170. PMC: 7058000. DOI: 10.1038/s41419-020-2360-0. View

17.

LeBleu V, Taduri G, OConnell J, Teng Y, Cooke V, Woda C . Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19(8):1047-53. PMC: 4067127. DOI: 10.1038/nm.3218. View

18.

Genovese G, Friedman D, Ross M, Lecordier L, Uzureau P, Freedman B . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5. PMC: 2980843. DOI: 10.1126/science.1193032. View

19.

Zheng Z, Deng G, Qi C, Xu Y, Liu X, Zhao Z . Porous Se@SiO nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress. Int J Nanomedicine. 2019; 14:215-229. PMC: 6312062. DOI: 10.2147/IJN.S184804. View

20.

Riehle M, Buscher A, Gohlke B, Kassmann M, Kolatsi-Joannou M, Brasen J . TRPC6 G757D Loss-of-Function Mutation Associates with FSGS. J Am Soc Nephrol. 2016; 27(9):2771-83. PMC: 5004639. DOI: 10.1681/ASN.2015030318. View